Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR-T Therapy Axicabtagene Ciloleucel – PR Newswire (press release)
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR–T Therapy Axicabtagene Ciloleucel
PR Newswire (press release) Jerrell Shelton, CEO of Cryoport, stated, "Kite's CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients' own immune cells to treat cancers. It offers hope to patients who previously had no other option left … |
